Clinical trial

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

NCT05766371

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-12-15

PhasePHASE2

Study timeline

Study start (actual)2023-12-15Date precision: day

Registry last updated2026-09-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Castrate Resistant Prostate Cancerunresolved

Metastatic Castration-resistant Prostate Cancerunresolved

Prostate Cancerunresolved

Prostate Carcinomaunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

177Lu-PSMA-617DRUG

Sponsors & collaborators

University of California, San Franciscolead sponsor

Merck Sharp & Dohme LLCcollaborator

Prostate Cancer Foundationcollaborator

Mapped research locations

San FranciscoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05766371 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.